Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
World Journal of Surgery
Erschienen in: World Journal of Surgery 11/2014

01.11.2014

Parafibromin, Galectin-3, PGP9.5, Ki67, and Cyclin D1: Using an Immunohistochemical Panel to Aid in the Diagnosis of Parathyroid Cancer

verfasst von: Peter P. Truran, Sarah J. Johnson, Richard D. Bliss, Thomas W. J. Lennard, Sebastian R. Aspinall

Erschienen in: World Journal of Surgery | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Parathyroid cancer is rare. Differentiating parathyroid carcinoma from degenerative changes at histopathology can be difficult and studies investigating the value of single immunohistochemical markers have had variable results. In this study we aimed to investigate whether a panel of immunohistochemistry markers could aid the diagnosis of parathyroid cancer.

Methods

All cases of parathyroid cancer at our institution from 1998 to 2012 were identified retrospectively. Cases were classified as definite cancers (those with evidence of metastatic spread) or histological cancers (those with features of carcinoma without evidence of metastasis). Controls with benign parathyroid disease were included for comparison. Immunohistochemistry for parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1 was analysed by an experienced endocrine pathologist.

Results

There were 24 cases and 14 benign adenomas. Four cases had evidence of metastatic spread and 20 were diagnosed on histological criteria alone. Sixteen of the 24 cases had further surgery with ipsilateral thyroid lobectomy and 15 also had a prophylactic level VI lymph node dissection. Apart from one patient with distant metastases at presentation, none developed recurrence at follow-up (median = 38 months). Immunohistochemistry results associated with parathyroid cancer were seen in 11/24 parafibromin, 13/24 galectin-3, 8/24 PGP9.5, 5/24 Ki67, and 2/24 cyclin D1. None of the controls had immunohistochemical staining suggestive of cancer. Nineteen of the 24 patients had at least one immunohistochemical result associated with parathyroid cancer (sensitivity 79 %, specificity 100 %). Cyclin D1 did not suggest malignancy in any case that did not already have another abnormal marker, and so did not add value to the panel in this study.

Conclusion

A panel of immunohistochemistry (PGP9.5, galectin-3, parafibromin, and Ki67) is better than any single marker and can be used to supplement classical histopathology in diagnosing parathyroid cancer.
Literatur
1.
Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM (2007) Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 109(9):1736–1741PubMedCrossRef
2.
Brown S, O’Neill C, Suliburk J, Sidhu S, Sywak M, Gill A et al (2011) Parathyroid carcinoma: increasing incidence and changing presentation. ANZ J Surg 81(7–8):528–532PubMedCrossRef
3.
Talat N, Schulte KM (2010) Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol 17(8):2156–2174PubMedCrossRef
4.
Evangelista L, Sorgato N, Torresan F, Boschin IM, Pennelli G, Saladini G et al (2011) FDG-PET/CT and parathyroid carcinoma: review of literature and illustrative case series. World J Clin Oncol 2(10):348–354PubMedCrossRefPubMedCentral
5.
Sidhu PS, Talat N, Patel P, Mulholland NJ, Schulte KM (2011) Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm. Eur Radiol 21(9):1865–1873PubMedCrossRef
6.
Horanyi J, Duffek L, Szlavik R, Takacs I, Toth M, Romics L Jr (2010) Intraoperative determination of PTH concentrations in fine needle tissue aspirates to identify parathyroid tissue during parathyroidectomy. World J Surg 34(3):538–543. doi:10.​1007/​s00268-009-0351-5 PubMedCrossRef
7.
Wei CH, Harari A (2012) Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol 13(1):11–23PubMedCrossRef
8.
Basu A, Sistla SC, Siddaraju N, Verma SK, Iyengar KR, Jagdish S (2008) Needle tract sinus following aspiration biopsy of papillary thyroid carcinoma: a case report. Acta Cytol 52(2):211–214PubMedCrossRef
9.
Agarwal G, Dhingra S, Mishra SK, Krishnani N (2006) Implantation of parathyroid carcinoma along fine needle aspiration track. Langenbecks Arch Surg 391(6):623–626PubMedCrossRef
10.
Karakas E, Muller HH, Lyadov VK, Luz S, Schneider R, Rothmund M et al (2012) Development of a formula to predict parathyroid carcinoma in patients with primary hyperparathyroidism. World J Surg 36(11):2605–2611. doi:10.​1007/​s00268-012-1707-9 PubMedCrossRef
11.
Ippolito G, Palazzo FF, Sebag F, De Micco C, Henry JF (2007) Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg 94(5):566–570PubMedCrossRef
12.
Schulte KM, Talat N (2012) Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol 8(10):612–622PubMedCrossRef
13.
Wang CA, Gaz RD (1985) Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg 149(4):522–527PubMedCrossRef
14.
15.
Cohn K, Silverman M, Corrado J, Sedgewick C (1985) Parathyroid carcinoma: the Lahey Clinic experience. Surgery 98(6):1095–1100PubMed
16.
Selvan B, Paul MJ, Seshadri MS, Thomas N, Paul T, Abraham D et al (2013) High index of clinical suspicion with optimal surgical techniques and adjuvant radiotherapy is critical to reduce locoregional disease progression in parathyroid carcinoma. Am J Clin Oncol 36(1):64–69PubMedCrossRef
17.
18.
Harari A, Waring A, Fernandez-Ranvier G, Hwang J, Suh I, Mitmaker E et al (2011) Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab 96(12):3679–3686PubMedCrossRef
19.
Erovic BM, Goldstein DP, Kim D, Mete O, Brierley J, Tsang R et al (2013) Parathyroid cancer: outcome analysis of 16 patients treated at the Princess Margaret Hospital. Head Neck 35(1):35–39PubMedCrossRef
20.
Johnson SJ (2010) Changing clinicopathological practice in parathyroid disease. Histopathology 56(7):835–851PubMedCrossRef
21.
22.
Chang YJ, Mittal V, Remine S, Manyam H, Sabir M, Richardson T et al (2006) Correlation between clinical and histological findings in parathyroid tumors suspicious for carcinoma. Am Surg 72(5):419–426PubMed
23.
24.
Kameyama K, Takami H (2005) Proposal for the histological classification of parathyroid carcinoma. Endocr Pathol 16(1):49–52PubMedCrossRef
25.
Rodriguez C, Naderi S, Hans C, Badoual C (2012) Parathyroid carcinoma: a difficult histological diagnosis. Eur Ann Otorhinolaryngol Head Neck Dis 129(3):157–159PubMedCrossRef
26.
DeLellis RA (2004) World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs. IARC Press, Lyon
27.
Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx SJ, Simonds WF (2005) Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 24(7):1272–1276PubMedCrossRef
28.
Iwata T, Mizusawa N, Taketani Y, Itakura M, Yoshimoto K (2007) Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen. Oncogene 26(42):6176–6183PubMedCrossRef
29.
Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C et al (2004) Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 10(19):6629–6637PubMedCrossRef
30.
Haven CJ, van Puijenbroek M, Tan MH, Teh BT, Fleuren GJ, van Wezel T et al (2007) Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol 67(3):370–376CrossRef
31.
Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D et al (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349(18):1722–1729PubMedCrossRef
32.
Witteveen JE, Hamdy NA, Dekkers OM, Kievit J, van Wezel T, Teh BT et al (2011) Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma. Mod Pathol 24(5):688–697PubMedCrossRef
33.
Juhlin CC, Villablanca A, Sandelin K, Haglund F, Nordenstrom J, Forsberg L et al (2007) Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 14(2):501–512PubMedCrossRef
34.
Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY et al (2009) Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer 115(2):334–344PubMedCrossRef
35.
Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG et al (2007) Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol 156(5):547–554PubMedCrossRef
36.
Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM et al (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30(9):1140–1149PubMedCrossRef
37.
O’Neill CJ, Chan C, Symons J, Learoyd DL, Sidhu SB, Delbridge LW et al (2011) Parathyroid carcinoma encountered after minimally invasive focused parathyroidectomy may not require further radical surgery. World J Surg 35(1):147–153. doi:10.​1007/​s00268-010-0826-4 PubMedCrossRef
38.
Howell VM, Gill A, Clarkson A, Nelson AE, Dunne R, Delbridge LW et al (2009) Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 94(2):434–441PubMedCrossRef
39.
Kim HK, Oh YL, Kim SH, Lee DY, Kang HC, Lee JI et al (2012) Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma. Head Neck 34(2):201–206PubMedCrossRef
40.
Wang O, Wang CY, Shi J, Nie M, Xia WB, Li M et al (2012) Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors. Chin Med J 125(16):2895–2901PubMed
41.
42.
Selvarajan S, Sii LH, Lee A, Yip G, Bay BH, Tan MH et al (2008) Parafibromin expression in breast cancer: a novel marker for prognostication? J Clin Pathol 61(1):64–67PubMedCrossRef
43.
Wilson PO, Barber PC, Hamid QA, Power BF, Dhillon AP, Rode J et al (1988) The immunolocalization of protein gene product 9.5 using rabbit polyclonal and mouse monoclonal antibodies. Br J Exp Pathol 69(1):91–104PubMedPubMedCentral
44.
Tokumaru Y, Yamashita K, Kim MS, Park HL, Osada M, Mori M et al (2008) The role of PGP9.5 as a tumor suppressor gene in human cancer. Int J Cancer 123(4):753–759PubMedCrossRefPubMedCentral
45.
Abbona GC, Papotti M, Gasparri G, Bussolati G (1995) Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol 26(2):135–138PubMedCrossRef
46.
Arvai K, Nagy K, Barti-Juhasz H, Petak I, Krenacs T, Micsik T et al (2012) Molecular profiling of parathyroid hyperplasia, adenoma and carcinoma. Pathol Oncol Res 18(3):607–614PubMedCrossRef
47.
Farnebo F, Auer G, Farnebo LO, Teh BT, Twigg S, Aspenblad U et al (1999) Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease. World J Surg 23(1):68–74. doi:10.​1007/​s002689900567 PubMedCrossRef
48.
Lloyd RV, Carney JA, Ferreiro JA, Jin L, Thompson GB, Van Heerden JA et al (1995) Immunohistochemical analysis of the cell cycle-associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinomas and adenomas. Endocr Pathol 6(4):279–287PubMedCrossRef
49.
Bergero N, De Pompa R, Sacerdote C, Gasparri G, Volante M, Bussolati G et al (2005) Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 36(8):908–914PubMedCrossRef
50.
Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR et al (2004) Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 45(5):493–500PubMedCrossRef
51.
Greco C, Vona R, Cosimelli M, Matarrese P, Straface E, Scordati P et al (2004) Cell surface overexpression of galectin-3 and the presence of its ligand 90 k in the blood plasma as determinants in colon neoplastic lesions. Glycobiology 14(9):783–792PubMedCrossRef
52.
Saggiorato E, Bergero N, Volante M, Bacillo E, Rosas R, Gasparri G et al (2006) Galectin-3 and Ki-67 expression in multiglandular parathyroid lesions. Am J Clin Pathol 126(1):59–66PubMedCrossRef
53.
Vasef MA, Brynes RK, Sturm M, Bromley C, Robinson RA (1999) Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol 12(4):412–416PubMed
54.
Hadar T, Shvero J, Yaniv E, Ram E, Shvili I, Koren R (2005) Expression of p53, Ki-67 and Bcl-2 in parathyroid adenoma and residual normal tissue. Pathol Oncol Res 11(1):45–49PubMedCrossRef
55.
Juhlin CC, Haglund F, Villablanca A, Forsberg L, Sandelin K, Branstrom R et al (2009) Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. Int J Oncol 34(2):481–492PubMed
56.
Juhlin CC, Nilsson IL, Johansson K, Haglund F, Villablanca A, Hoog A et al (2010) Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 21(3):166–177PubMedCrossRef
57.
Osawa N, Onoda N, Kawajiri H, Tezuka K, Takashima T, Ishikawa T et al (2009) Diagnosis of parathyroid carcinoma using immunohistochemical staining against hTERT. Int J Mol Med 24(6):733–741PubMed
58.
Onoda N, Ogisawa K, Ishikawa T, Takenaka C, Tahara H, Inaba M et al (2004) Telomerase activation and expression of its catalytic subunits in benign and malignant tumors of the parathyroid. Surg Today 34(5):389–393PubMedCrossRef
59.
Kammori M, Nakamura K, Ogawa T, Mafune K, Tatutomi Y, Obara T et al (2003) Demonstration of human telomerase reverse transcriptase (hTERT) in human parathyroid tumours by in situ hybridization with a new oligonucleotide probe. Clin Endocrinol 58(1):43–48CrossRef
60.
McCourt CM, Boyle D, James J, Salto-Tellez M (2013) Immunohistochemistry in the era of personalised medicine. J Clin Pathol 66(1):58–61PubMedCrossRef
61.
Solcia E, Klöppel G, Sobin LH, Capella C, DeLellis RA, Heitz PU, Horvath E, Kovacs K, Lack E et al (2000) World Health Organization International Histological Classification of Tumours: histological typing of endocrine tumours, 2nd edn. Springer, New York
62.
Kameyama K, Takami H, Umemura S, Osamura YR, Wada N, Sugino K et al (2000) PCNA and Ki-67 as prognostic markers in human parathyroid carcinomas. Ann Surg Oncol 7(4):301–304PubMedCrossRef
Metadaten
Titel
Parafibromin, Galectin-3, PGP9.5, Ki67, and Cyclin D1: Using an Immunohistochemical Panel to Aid in the Diagnosis of Parathyroid Cancer
verfasst von
Peter P. Truran
Sarah J. Johnson
Richard D. Bliss
Thomas W. J. Lennard
Sebastian R. Aspinall
Publikationsdatum
01.11.2014
Verlag
Springer US
Erschienen in
World Journal of Surgery / Ausgabe 11/2014
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-014-2700-2

Weitere Artikel der Ausgabe 11/2014

World Journal of Surgery 11/2014 Zur Ausgabe

OriginalPaper

A Randomized Prospective Study Comparing Acquisition of Laparoscopic Skills in Three-Dimensional (3D) vs. Two-Dimensional (2D) Laparoscopy

OriginalPaper

Changing Trends in Thyroid and Parathyroid Surgery over the Decade: Is Same-day Discharge Feasible in the United Kingdom?

OriginalPaper

Lateral Incisional Hernia After Renal Transplantation: A Comparative Study

OriginalPaper

Is Radical Surgery Feasible in Liver Hydatid Cysts in Contact with the Inferior Vena Cava?

OriginalPaper

A Novel Method for Laparoscopic Splenectomy in the Setting of Hypersplenism Secondary to Liver Cirrhosis: Ten Years’ Experience

OriginalPaper

Role of Pancreatic Juice Cytology in the Preoperative Management of Intraductal Papillary Mucinous Neoplasm of the Pancreas in the Era of International Consensus Guidelines 2012

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.